PD-1/PD-L1 Immunotherapy Market Report

Global and Region PD-1/PD-L1 Immunotherapy Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：137
  • REPORT CODE：GMM882679
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of PD-1/PD-L1 Immunotherapy market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of PD-1/PD-L1 Immunotherapymarket, defines the market attractiveness level of PD-1/PD-L1 Immunotherapy market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of PD-1/PD-L1 Immunotherapy industry, describes the types of PD-1/PD-L1 Immunotherapy market, the applications of major players and the market size, and deeply analyzes the current situation of the global PD-1/PD-L1 Immunotherapy market and the development prospects and opportunities of PD-1/PD-L1 Immunotherapy industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global PD-1/PD-L1 Immunotherapy market in Chapter 13.

    By Player:

    • Pfizer Inc

    • BeiGene Ltd

    • GlaxoSmithKline plc

    • Innovent Biologics Inc

    • Jiangsu HengRui Medicine Co Ltd

    • Chia Tai Tianqing Pharmaceutical Group Co Ltd

    • Eli Lilly & Company

    • Merck & Co Inc

    • Regeneron Pharmaceuticals Inc

    • Sanofi SA

    • AstraZeneca Plc

    • Novartis AG

    • F Hoffmann-La Roche Ltd

    • Bristol-Myers Squibb Company

    By Type:

    • PD-1 Inhibitors

    • PD-L1 Inhibitors

    By End-User:

    • Non-Small Cell Lung Cancer

    • Esophageal Cancer

    • Urothelial Carcinoma

    • Hepatocellular Carcinoma

    • Small Cell Lung Cancer

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 PD-1/PD-L1 Immunotherapy Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 PD-1/PD-L1 Immunotherapy Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 PD-1/PD-L1 Immunotherapy Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 PD-1/PD-L1 Immunotherapy Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise PD-1/PD-L1 Immunotherapy Market Analysis and Outlook to 2022

    • 7.1 Global PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.2 United States PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.3 Europe PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.4 China PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.5 Japan PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.6 India PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    • 7.7 South Korea PD-1/PD-L1 Immunotherapy Consumption (2017-2022)

    8 Region and Country-wise PD-1/PD-L1 Immunotherapy Market Analysis and Outlook to 2028

    • 8.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.2 United States PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.3 Europe PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.4 China PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.5 Japan PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.6 India PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    • 8.7 South Korea PD-1/PD-L1 Immunotherapy Consumption Forecast (2022-2028)

    9 Global PD-1/PD-L1 Immunotherapy Market Outlook by Types and Applications to 2022

    • 9.1 Global PD-1/PD-L1 Immunotherapy Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)

    • 9.2 Global PD-1/PD-L1 Immunotherapy Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Esophageal Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

      • 9.2.6 Global Others Consumption and Growth Rate (2017-2022)

    10 Global PD-1/PD-L1 Immunotherapy Market Outlook by Types and Applications to 2028

    • 10.1 Global PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Esophageal Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.6 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global PD-1/PD-L1 Immunotherapy Import and Export Analysis (Top 5 Countries)

    • 11.1 Global PD-1/PD-L1 Immunotherapy Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global PD-1/PD-L1 Immunotherapy Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 PD-1/PD-L1 Immunotherapy Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global PD-1/PD-L1 Immunotherapy Market Competitive Analysis

    • 14.1 Pfizer Inc

      • 14.1.1 Pfizer Inc Company Details

      • 14.1.2 Pfizer Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pfizer Inc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.2 BeiGene Ltd

      • 14.2.1 BeiGene Ltd Company Details

      • 14.2.2 BeiGene Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 BeiGene Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • 14.3 GlaxoSmithKline plc

      • 14.3.1 GlaxoSmithKline plc Company Details

      • 14.3.2 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.4 Innovent Biologics Inc

      • 14.4.1 Innovent Biologics Inc Company Details

      • 14.4.2 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.5 Jiangsu HengRui Medicine Co Ltd

      • 14.5.1 Jiangsu HengRui Medicine Co Ltd Company Details

      • 14.5.2 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • 14.6 Chia Tai Tianqing Pharmaceutical Group Co Ltd

      • 14.6.1 Chia Tai Tianqing Pharmaceutical Group Co Ltd Company Details

      • 14.6.2 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • 14.7 Eli Lilly & Company

      • 14.7.1 Eli Lilly & Company Company Details

      • 14.7.2 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product and Service

    • 14.8 Merck & Co Inc

      • 14.8.1 Merck & Co Inc Company Details

      • 14.8.2 Merck & Co Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Merck & Co Inc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.9 Regeneron Pharmaceuticals Inc

      • 14.9.1 Regeneron Pharmaceuticals Inc Company Details

      • 14.9.2 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.10 Sanofi SA

      • 14.10.1 Sanofi SA Company Details

      • 14.10.2 Sanofi SA PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Sanofi SA PD-1/PD-L1 Immunotherapy Product and Service

    • 14.11 AstraZeneca Plc

      • 14.11.1 AstraZeneca Plc Company Details

      • 14.11.2 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product and Service

    • 14.12 Novartis AG

      • 14.12.1 Novartis AG Company Details

      • 14.12.2 Novartis AG PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Novartis AG PD-1/PD-L1 Immunotherapy Product and Service

    • 14.13 F Hoffmann-La Roche Ltd

      • 14.13.1 F Hoffmann-La Roche Ltd Company Details

      • 14.13.2 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • 14.14 Bristol-Myers Squibb Company

      • 14.14.1 Bristol-Myers Squibb Company Company Details

      • 14.14.2 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of PD-1/PD-L1 Immunotherapy

    • Figure PD-1/PD-L1 Immunotherapy Picture

    • Table Global PD-1/PD-L1 Immunotherapy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global PD-1/PD-L1 Immunotherapy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global PD-1/PD-L1 Immunotherapy Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global PD-1/PD-L1 Immunotherapy Consumption by Country (2017-2022)

    • Figure United States PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Table Europe PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure China PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Japan PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure India PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure South Korea PD-1/PD-L1 Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global PD-1/PD-L1 Immunotherapy Consumption Forecast by Country (2022-2028)

    • Figure United States PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure China PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure India PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea PD-1/PD-L1 Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PD-1 Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global PD-L1 Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Non-Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Esophageal Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Urothelial Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)

    • Figure Global Small Cell Lung Cancer Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global PD-1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global PD-L1 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Non-Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Esophageal Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Urothelial Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Small Cell Lung Cancer Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global PD-1/PD-L1 Immunotherapy Import by Region (Top 5 Countries) (2017-2028)

    • Table Global PD-1/PD-L1 Immunotherapy Export by Region (Top 5 Countries) (2017-2028)

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc PD-1/PD-L1 Immunotherapy Product and Service

    • Table BeiGene Ltd (Foundation Year, Company Profile and etc.)

    • Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table BeiGene Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • Table GlaxoSmithKline plc (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Product and Service

    • Table Innovent Biologics Inc (Foundation Year, Company Profile and etc.)

    • Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Innovent Biologics Inc PD-1/PD-L1 Immunotherapy Product and Service

    • Table Jiangsu HengRui Medicine Co Ltd (Foundation Year, Company Profile and etc.)

    • Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Jiangsu HengRui Medicine Co Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • Table Chia Tai Tianqing Pharmaceutical Group Co Ltd (Foundation Year, Company Profile and etc.)

    • Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Chia Tai Tianqing Pharmaceutical Group Co Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • Table Eli Lilly & Company (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly & Company PD-1/PD-L1 Immunotherapy Product and Service

    • Table Merck & Co Inc (Foundation Year, Company Profile and etc.)

    • Table Merck & Co Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co Inc PD-1/PD-L1 Immunotherapy Product and Service

    • Table Regeneron Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Inc PD-1/PD-L1 Immunotherapy Product and Service

    • Table Sanofi SA (Foundation Year, Company Profile and etc.)

    • Table Sanofi SA PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi SA PD-1/PD-L1 Immunotherapy Product and Service

    • Table AstraZeneca Plc (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Plc PD-1/PD-L1 Immunotherapy Product and Service

    • Table Novartis AG (Foundation Year, Company Profile and etc.)

    • Table Novartis AG PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG PD-1/PD-L1 Immunotherapy Product and Service

    • Table F Hoffmann-La Roche Ltd (Foundation Year, Company Profile and etc.)

    • Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Product and Service

    • Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company PD-1/PD-L1 Immunotherapy Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US